A new prescription eye drop is giving adults with age related reading difficulty another way to see close print, with clinical trials showing several hours of improved near vision after a daily dose. VIZZ, approved by the U.S. Food and Drug Administration in July 2025, may allow some people to put aside their reading glasses for part of the day. Its effect is temporary, and the same change that sharpens nearby text can make vision seem dimmer in poor light.
VIZZ treats presbyopia, the gradual loss of near focusing ability that commonly becomes noticeable in a person’s 40s. The change often announces itself through ordinary tasks: a phone held farther away, a menu brought under a brighter lamp or a medication label that suddenly requires readers. The eye’s lens becomes less flexible with age, making it harder to bring close objects into focus.
The drops contain aceclidine, which constricts the pupils. Smaller pupils increase the range of distances that appear sharp, much as a camera can bring more of a scene into focus when its aperture narrows. The medication does not restore the lens’s flexibility or halt the progression of presbyopia. Its effect fades, and continued benefit requires another prescribed dose on a later day.
The FDA approved VIZZ on the strength of controlled clinical trials that measured improvement in near vision while monitoring distance vision. Three hours after treatment, 65% of VIZZ users in one trial and 71% in another improved by at least three lines on a near vision chart without losing a line of corrected distance vision. Far fewer participants in the comparison groups met that measure. The results establish a real benefit, although chart performance cannot predict whether an individual will comfortably read every screen, label or page without glasses.
The approved regimen calls for one drop in each eye, followed two minutes later by a second drop in each eye, once daily. Near vision may improve within about 30 minutes, with an effect lasting up to 10 hours. Duration and clarity vary among users. Anyone who needs dependable near vision beyond those hours will still need another means of correction.
For adults who move through a workday checking messages, reading documents and handling other close tasks, that window of clearer vision may be useful. The drops could also appeal to someone who wears readers only occasionally and finds them inconvenient. They are less likely to eliminate glasses for a person who needs sustained clarity for fine print or detailed work. People who wear prescription lenses to see at a distance should not expect VIZZ to correct that separate need.
Distance vision itself was part of the trials’ effectiveness measure: participants had to gain near vision without losing a specified amount of corrected distance vision. Yet the medication can change the quality of vision in ways that matter outside an exam room. Sixteen percent of trial participants reported dim vision. A smaller pupil lets less light into the eye, which can make poorly lit settings more difficult even when a distance vision chart shows no meaningful loss.
The prescribing information warns patients to avoid driving or operating machinery whenever their vision is unclear and to use particular caution when driving at night. Someone considering VIZZ should think about when they would take it and what they need to do afterward. A drop that helps with afternoon reading may be a poor fit if it leaves that person uncomfortable behind the wheel after dark.
Other side effects were also reported in the trials. Irritation when the drops were applied affected 20% of participants, while 13% reported headaches. Most reactions were mild and temporary. Those figures nonetheless give patients a more useful picture than a promise of freedom from reading glasses: the treatment offers convenience to some users at the cost of daily medication and a possibility of discomfort.
The prescribing information carries a more serious warning involving the retina. Rare retinal tears and detachments have been reported with medications that constrict the pupil. A retinal examination is advised before starting VIZZ. Sudden flashes of light, new floaters or vision loss require immediate medical care. A history of eye inflammation, including inflammation of the iris, is also information a patient should discuss with the prescribing doctor.
VIZZ’s recent approval adds another consideration. Two six week trials supplied the principal evidence that it improves near vision, and a separate six month trial supported its safety evaluation. The FDA concluded that the benefits outweigh the known risks for adults with presbyopia. Longer experience in everyday use will provide more information about uncommon reactions and what patients can expect after years of treatment.
An eye examination remains the starting point because trouble reading nearby text does not, by itself, establish presbyopia as the only cause. An outdated prescription, cataracts or another eye condition may call for a different response. An optometrist or ophthalmologist can identify the cause, examine the retina and assess whether a pupil constricting medication suits the patient’s vision needs and daily routine.
For the right patient, VIZZ offers something reading glasses cannot: several hours of improved near vision without putting on a pair of lenses. For others, glasses remain the clearer and simpler choice, especially for extended reading, precise close work or frequent activity in low light. The question is not whether a prescription drop can improve near vision. Clinical trials show that it can. The question for each patient is whether that improvement lasts when they need it, feels comfortable in the settings where they use their eyes and outweighs the risks of daily treatment.